AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Attovia Therapeutics, Inc.
Video analysis: ATTO
All videosNo video analysis for this stock yet. Request one from our team.
News: ATTO
Attovia Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026
Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More
Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that could reshape your portfolio heading into a volatile fall.
Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source
Attovia Therapeutics (NASDAQ:ATTO) has arrived on public markets with a pipeline built entirely on one bet: that a biparatopic antibody platform called Attobody can turn well-validated immunology targets into next-generation biologics.
Attovia Therapeutics (NASDAQ:ATTO) Director Acquires $1,785,000.00 in Stock
Attovia Therapeutics, Inc. (NASDAQ: ATTO - Get Free Report) Director Colin Walsh purchased 85,000 shares of the firm's stock in a transaction dated Wednesday, August 5th. The stock was bought at an average cost of $21.00 per share, for a total transaction of $1,785,000.00. Following the acquisition, the director directly owned 85,000 shares in the company,
Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Global Strategic Fund Venbio Purchases 382,352 Shares of Stock
Attovia Therapeutics, Inc. (NASDAQ: ATTO - Get Free Report) major shareholder Global Strategic Fund Venbio purchased 382,352 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The shares were purchased at an average cost of $17.00 per share, with a total value of $6,499,984.00. Following the completion of the acquisition, the
Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Redmile Group, Llc Purchases 200,000 Shares
Attovia Therapeutics, Inc. (NASDAQ: ATTO - Get Free Report) major shareholder Redmile Group, Llc bought 200,000 shares of Attovia Therapeutics stock in a transaction on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, with a total value of $3,400,000.00. Following the completion of the acquisition, the insider owned 982,854
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the closing of its upsized initial public offering of 19,550,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,550,000 additional shares, at the initial public offering price of $17.00 per share. The aggregate gross proceeds to Attovia from the initial public offering were approximately $332.4 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares were offered by Attovia. Attovia's common stock began trading on the Nasdaq Global Market on August 5, 2026, under the symbol “ATTO.”